02 Jun 2024 06:11 CEST

Issuer

SoftOx Solutions AS

A peer-reviewed article describing a study investigating the safety and
tolerability as well as wound size effect and antimicrobial efficacy of SOftOx
Biofilm Eradicator has just been accepted by the top ranked medical wound
journal “Advances in Wound Care”.

“The conclusion in the study is very interesting. It shows SBE is safe and
tolerable in humans. In addition SBE reduced the bioburden and strongly improved
wound closure”, says Thomas Bjarnsholt, professor at Copenhagen University.

A first-in-human clinical study investigating the safety and tolerability of
stabilized hypochlorous acid in patients with chronic leg ulcers | Advances in
Wound Care (liebertpub.com)

Link to the published article:
https://www.liebertpub.com/doi/10.1089/wound.2024.0040?url_ver=Z39.88-2003&rfr_i
d=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed


Source

SoftOx Solutions AS

Provider

Oslo Børs Newspoint

Company Name

SOFTOX SOLUTIONS

ISIN

NO0010811961

Symbol

SOFTX

Market

Euronext Growth